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INTRODUCTION 
Hepatocellular carcinoma (HCC) is an important public health 
problem. It has an identifiable latent period, which necessitates 
an effective routine surveillance program.1 Small HCCs detected 
by routine surveillance can often be cured with a good prognosis 
(>50% 5-year disease-free survival rate), whereas HCCs detected 
after the onset of symptoms have a poor prognosis (≤10% 5-year 
survival rate).2 Furthermore, a randomized controlled study and a 
few uncontrolled studies have shown that HCC surveillance im-
proves survival rates.3-5 Hence, HCC surveillance is widely used 
and recommended for at-risk populations.2,6,7
The surveillance process involves determining at-risk popula-
tions (who should enter the surveillance program), the surveillance 
(diagnostic) test, and the surveillance interval (how frequently the 
tests should be done). Although complete consensus has yet to be 
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reached on all three issues, the dilemmas faced by physicians car-
ing for high-risk patients stem mainly from determining the opti-
mal surveillance interval.8 The optimal surveillance interval is de-
termined based on the tumor size and growth rate in order to 
detect HCCs at a stage when treatment is likely to produce a 
cure.9,10 While the ideal HCC surveillance interval is not known, in-
tervals ranging from 3-12 months have been proposed.2,11,12 Cur-
rently, the American Association for the Study of Liver Diseases 
(AASLD), the European Association for the Study of Liver (EASL), 
and the Asian Pacific Association for the Study of the Liver 
(APASL) recommend that surveillance be conducted at 6-month 
intervals.2 This recommendation is based on the assumption that 
the HCC growth rate is similar in every patient. However, tumor 
growth in general is strongly affected by the microenvironment,13 
and HCC doubling time is likely affected by host factors as well as 
by tumor factors.
Several previous studies have investigated HCC growth rates in 
order to determine the optimal surveillance or follow-up interval 
and reported several host factors that may affect the HCC growth 
rate, including sex, the doubling time of alpha-fetoprotein (AFP), 
and the presence of hepatitis B surface antigen (HBsAg).14-22 Those 
studies all had small sample sizes (fewer than 30 cases, even in 
the largest series), however, and reported a wide range of tumor 
volume doubling times (TVDTs) and inconsistent results for the 
significance of host factors. Therefore, we examined a relatively 
large number (n=175) of untreated HCCs in patients with cirrhotic 
liver disease to obtain more solid estimates of TVDT and identify 
host factors that can significantly affect TVDT.
PATIENTS AND METHODS
Study population 
This study was approved by the local institutional review boards 
of the two participating hospitals, and patient informed consent 
was waived. By searching the electronic database, we identified 
15,890 patients diagnosed with HCC and underlying chronic liver 
disease between January 1, 2001 and December 31, 2010 at two 
tertiary care hospitals in Seoul, Korea. Two radiologists (C.A. and 
Y.A.C.) reviewed the medical records and imaging studies of each 
patient and identified 181 patients who met the following inclu-
sion criteria: (1) untreated HCC detected by 3-phase or 4-phase 
dynamic CT or MRI with a slice thickness of 5 mm or less, (2) at 
least one follow-up 3-phase or 4-phase dynamic CT or MRI scan, 
(3) an interval of at least 1 month between the initial and follow-
up studies without any anti-cancer treatment, and (4) met the Mi-
lan criteria (solitary HCC with a diameter ≤5 cm or up to 3 HCCs 
with diameters ≤3 cm and no extrahepatic manifestation or vas-
cular invasion). Six patients were excluded because they had ei-
ther combined infection with hepatitis B virus (HBV) and hepatitis 
C virus (HCV) (n=4) or a solitary HCC with a nodule in nodule ap-
pearance (n=2). We defined HCC as either (1) a tumor >1 cm in 
diameter with arterial enhancement and venous/delayed washout, 
(2) a hypervascular tumor >1 cm in diameter that had grown ei-
ther more than 5 mm or more than 50% in diameter since the 
previous exam, or (3) a tumor that was pathologically confirmed 
by biopsy within a month of initial detection. Our final study pop-
ulation comprised 175 patients with a combined total of 204 
HCCs (122 men and 53 women; mean age, 60 years; age range, 
21-85 years). Of these 204 HCCs, 164 (80.4%) were defined as 
HCC because they were > 1cm and showed the typical enhance-
ment pattern (arterial enhancement and venous/delayed wash-
out); 21 (10.3%), hypervascular tumors > 1cm that had grown; 9 
(4.4%), both showed the typical enhancement pattern and had 
grown; and 10 (4.9%), confirmed by biopsy. These 175 patients 
did not receive treatment during the observation period because 
treatment was delayed (n=92), treatment was refused (n=36), the 
initial diagnosis was uncertain or incorrect (n=20), the operative 
risk was high due to severe liver impairment or comorbidity 
(n=19), or the patients were waiting for liver transplantation 
(n=8). One hundred thirty-six of the patients eventually received 
treatment, which included loco-regional treatments such as trans-
arterial chemoembolization or radiofrequency ablation (n=101), 
hepatic resection (n=20), liver transplantation (n=10), and che-
motherapy with or without local radiation therapy (n=5). The re-
maining 39 patients did not receive treatment before loss to fol-
low-up or death, primarily because they refused treatment or their 
physicians expected high morbidity or mortality related to the 
treatment.
Data collection
Electronic medical records were reviewed to obtain the clinical 
and laboratory data recorded for each patient within the first 
month before or after the initial imaging study. The clinical data 
included patient demographics, etiology of chronic liver disease, 
alcohol consumption, medication history, the presence of hepatic 
encephalopathy, and the type of treatment received. Alcohol in-
take was considered significant if it exceeded 25 g/day on aver-
age.23 Laboratory data included levels of alanine aminotransferase 
(ALT), AFP, protein induced by vitamin K absence (PIVKA-II), albu-
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min, bilirubin, international normalized ratio (INR), serologic mark-
ers of viral hepatitis, and HBV DNA. The reference values used for 
AFP and PIVKA-II levels were <9 ng/mL and <40 mAU/mL, re-
spectively. Chronic HBV infection was determined based on serum 
positivity for HBsAg for at least 6 months. Chronic HCV infection 
was determined based on serum positivity for both anti-HCV and 
HCV-RNA for at least 6 months. HBV DNA load was measured by 
the Digene hybrid capture assay (Digene Diagnostics, Beltsville, 
MD, USA), with a lower limit of 0.5 pg/mL, or by the fully auto-
mated COBAS AmpliPrep-COBAS Taqman 96 system (Roche Mo-
lecular Systems, Branchburg, NJ, USA), with a linear detection 
range of 20-170,000,000 IU/mL. The radiologists recorded the 
number and location of HCCs and the presence of ascites on the 
basis of CT and/or MRI scans. Child-Pugh score was calculated for 
each patient.
 
Measurement of tumor volume doubling time 
This study included 3-phase and 4-phase contrast-enhanced 
dynamic CT and MRI studies. When more than two imaging stud-
ies were available, we selected two for TVDT calculation accord-
ing to the following principles. First, two studies with the same 
imaging modality were chosen whenever possible. Second, if a 
patient had multiple follow-up examinations with the same imag-
ing modality, only the follow-up with the maximum interval was 
used. Third, MRI was preferred over CT. The interval between the 
initial and last imaging studies ranged from 30 to 777 days (mean, 
140 days; median, 91 days).
Two radiologists (M.S.P. and D.C.) who were unaware of the 
patients’ clinical information measured the size of each HCC using 
the best available image of the tumor, with preference given to 
delayed images followed by portal phase images and finally arte-
rial phase images. The average tumor diameter was calculated 
from the two greatest perpendicular dimensions, as measured on 
transverse images. The tumor size was then used to determine 
the tumor volume (TV) calculated as TV = (4/3) × π × (D/2)3, 
where D is the average diameter. On follow-up imaging, the same 
plane of section was used to measure the tumor size and volume. 
The growth rate of the HCC was expressed as TVDT calculated us-
ing Schwartz’s equation24: TVDT = (T - T0) × log2 / (log V/V0), 
where (T - T0) indicates the time interval between two measure-
ments, and V0 and V represent the tumor volumes at the two 
measurement times. Based on the calculated TVDT, the time 
needed for each 1 cm increase in tumor diameter was also calcu-
lated.
Statistical analysis 
The TVDT was distributed lognormally. A Kolmogorov-Smirnov 
test revealed that the TVDT was normally distributed after log 
transformation (P>0.15). Therefore, we used the log-transformed 
TVDT for statistical analysis. To analyze the TVDT among the pa-
tients, the HCC with the shortest doubling time was chosen for 
each patient that had multiple HCCs. Univariate and multivariate 
linear regression analyses were performed to find factors affect-
ing the TVDT. The variables investigated were age, sex, alcohol 
consumption, antiviral medication, Child-Pugh class, virus type, 
serum AFP/PIVKA-II levels, AFP doubling time, initial average HCC 
diameter, and tumor multiplicity. Possible interactions of these 
variables with the different hospitals were tested in terms of their 
effects on TVDT. An ANOVA followed by Bonferroni post-hoc 
tests was performed to compare the TVDT among the different vi-
rus types. The relationship between the TVDT and the initial tu-
mor diameter was estimated by a linear regression equation. Vari-
ables with alpha <0.05 in the univariate analysis were included in 
the multivariate analysis. The correlation between each factor in 
the multivariate analysis and the TVDT was analyzed using the 
Spearman rank correlation test. Two-sided P-values <0.05 were 
considered statistically significant. All statistical analyses were 
performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Baseline patient and tumor characteristics 
The patient and tumor characteristics are summarized in Table 1. 
Among the 175 patients, 116 (66.3%) and 37 (21.1%) were in-
fected with HBV and HCV, respectively, and the remaining 22 
(12.6%) were not chronic carriers of hepatitis virus. Of the 161 
patients who could be given Child-Pugh scores, 117 (74.1%) were 
categorized as Child A, 26 (16.5%) as Child B, and 15 (9.5%) as 
Child C. Among the patients for whom the data were available, 
33.5% (54/161) and 56.7 % (55/97) had normal AFP and PIVKA-
II, respectively. We obtained the AFP doubling time for 132 pa-
tients, and 47 (35.6%) of those had stable or decreasing AFP lev-
els during the observation period. A total of 31 patients received 
antiviral medication during the observation period: 22 received 
lamivudine (Zeffix; GlaxoSmithKline, Greenford, UK); 4 received 
adefovir (Hepsera; Gilead Sciences Inc., Foster City, CA, USA); 3 
received entecavir (Baraclude; Bristol-Myers Squibb, Princeton, 
NJ, USA); 1 received both lamivudine and adefovir; and 1 received 
a combination of pegylated interferon α-2a (Pegasys; Roche, 
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Seoul, Korea) and ribavirin (Viramid; Ilsung Pharmaceuticals, 
Seoul, Korea). Twenty-two patients (12.6%) had more than 1 
HCC: 15 had 2 HCCs, and 7 had 3 HCCs. The initial tumor diame-
ter ranged from 1 to 4.6 cm, with a median of 1.5 cm; Of 175 
HCCs, 94 (53.7%) were 1.5 cm or smaller, 34 (19.4%) were be-
tween 1.5 cm and 2 cm, and the remaining 47 (26.9%) were larg-
er than 2 cm. One hundred twenty-six HCCs (72%) were found in 
the right hepatic lobe, while the other 49 (28%) were found in the 
left or caudate lobe. 
Tumor volume doubling time and associated factors
The TVDT ranged from 11 to 851.2 days (mean ± SD, 127.6 ± 
128.7; median, 85.7 days), and its geometric mean ± SD, comput-
ed by reverse-transforming the mean of the log-transformed val-
ues, was 91.4 ± 2.2. The univariate linear regression showed that 
a shorter TVDT was significantly associated with serum AFP ≥
400 ng/mL (vs. <9 ng/mL), smaller initial tumor diameter, and 
HBV infection. In the multivariate analysis, virus type (HBV vs. 
HCV, P=0.0234) and initial tumor diameter (P=0.0204) were in-
dependently associated with TVDT (Table 2). None of the vari-
ables investigated showed a significant interaction with hospital, 
so a subgroup analysis by hospital was not performed. The TVDT 
was shortest among the patients infected with HBV (median 
[range], 76.8 [11-752.2] days), longest among those infected with 
HCV (median [range], 137.2 [22.4-851.2] days), and intermediate 
among those with no hepatitis virus infection (median [range], 
99.8 [33.6-288.4] days). There was a significant difference in 
Table 1. Patient and tumor characteristics
Variables Patients (n = 175)
Age (years), mean±SD 60±9.4
Sex (male/female) 126/53
Alcohol consumption
   None 104 (67.1)
   Occasional (≤25 g/day)   12 (7.7)
   Significant (>25 g/day)      39 (25.2)
   NA 20
Anti-viral medication     31 (17.7)
Etiology of liver disease
   HBV/HCV/non-viral 116 (66.3)/37 (21.1)/
22 (12.6)
Child-Pugh class
   A/B/C/NA 117 (74.1)/26 (16.5)/
15 (9.5)/17
AFP (ng/mL)
   ≤9 54 (33.5)
   >9 and ≤400 93 (57.8)
   >400 14 (8.7)
   NA 14
PIVKA-II (mAU/mL)
   ≤40 55 (56.7)
   >40 and ≤400 29 (29.9)
   >400 13 (13.4)
   NA 78
Doubling time of AFP (days)
   Stable or decreased 47 (35.6)
   >0 and ≤150 42 (31.8)
   >150 43 (32.6)
   NA 43
Tumor multiplicity 22 (12.6)
Initial tumor diameter (cm)
   1.5 94 (53.7)
   >1.5 and 2 34 (19.4)
   >2 and 3 40 (22.9)
   >3 and 5 7 (4)
TVDT (days)
    Median (range)/ geometric mean±SD 85.7 (11-851.2)/ 91.4±2.2
Values are presented as median (range) or n (%), unless stated otherwise. 
Percentages were calculated after excluding missing cases (if any). 
SD, standard deviation; NA, not assessable; HBV, hepatitis B virus; HCV, 
hepatitis C virus; AFP, alpha fetoprotein; PIVKA-II, protein induced by vitamin 
K absence; TVDT, tumor volume doubling time.
Figure 1. Difference in the TVDT according to virus type. HBV, HCV, and 
Non-B Non-C represent patients infected with HBV, infected with HCV, 
and not infected with hepatitis virus, respectively. CI, confidence interval. 
*Statistically significant based on ANOVA followed by post-hoc Bonfer-
roni analysis. TVDT, tumor volume doubling time; HBV, hepatitis B virus; 
HCV, hepatitis C virus.
P=0.2994
P=0.1226
*P=0.0008
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TVDT between the patients infected with HBV and those infected 
with HCV (P<0.001) but not between those with no hepatitis vi-
rus infection and those with either HBV or HCV infection (no virus 
vs. HBV, P=0.1226; no virus vs. HCV, P=0.2994; Fig. 1). There 
was a positive linear relationship between the log-transformed 
TVDT and the initial diameter of the HCC (R2=0.027; Fig. 2). The 
linear regression equations for the entire study cohort and the vi-
rus-type subgroups were as follows: for all patients, TVDT = exp 
(0.173 × diameter + 4.211); for patients with HBV, TVDT = exp 
(0.124 × diameter + 4.161); for patients with HCV, TVDT = exp 
(0.221 × diameter + 4.475); and for patients with no hepatitis vi-
rus, TVDT = exp (0.316 × diameter + 4.094).
We used the regression equations to calculate the time it would 
take an HCC to increase its diameter by 1 cm based on its initial 
diameter (from 1 cm to 5 cm) and the virus type (HBV, HCV, or no 
virus) (Table 3). The estimated time needed for a HCC to grow 
from 1 cm to 2 cm was 212 days in patients with HBV infection 
and 328 days in those with HCV infection. 
DISCUSSION
No prospective study has been performed to evaluate the HCC 
doubling time, and it is highly unlikely for ethical and practical 
reasons that one will ever be performed. The available evidence 
regarding the natural course of untreated HCC comes from retro-
Table 2. Univariate and multivariate linear regression analyses to determine the factors related to the TVDT of untreated HCC
Univariate Multivariate
Beta SE P-value Beta SE P-value
Age (years)* 0.005 0.006 0.4044
Sex (vs. male)
    Female 0.023 0.131 0.8592
Alcohol (vs. none)
    Occasional (≤25 g/day) -0.327 0.242 0.1779
Significant (>25 g/day) -0.072 0.145 0.6197
Anti-viral medication -0.054 0.147 0.7139
Multiplicity of tumor -0.063 0.178 0.7238
Child-Pugh class (vs. A)
    B 0.204 0.177 0.2516
    C -0.148 0.224 0.5102
AFP (vs. ≤9)
    9-400 -0.021 0.133 0.8770 0.030 0.134 0.8213
    ≥400 -0.546 0.235 0.0216 -0.458 0.232 0.0531
PIVKA-II (vs. ≤40)
    40-400 0.029 0.181 0.8724
    ≥400 -0.126 0.229 0.5836
Doubling time of AFP (vs. <0)
    0-150 -0.305 0.158 0.0553
    ≥150 0.144 0.156 0.3568
Virus (vs. HBV)
    None 0.278 0.179 0.1226 0.256 0.192 0.1851
    HCV 0.493 0.144 0.0008 0.352 0.154 0.0234
Initial diameter* 0.174 0.078 0.0269 0.198 0.084 0.0204
Variables with alpha <0.05 in the univariate analysis were included in the multivariate analysis. 
*Beta was calculated per an increment of 1 year or 1 cm.
TVDT, tumor volume doubling time; HCC, hepatocellular carcinoma; SE, standard error; AFP, alpha fetoprotein; PIVKA-II, protein induced by vitamin K absence; 
HBV, hepatitis B virus; HCV, hepatitis C virus.
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spective studies. To our knowledge, our study is the largest series 
(175 patients) yet reported in the literature.
Our study shows that the growth rate of HCC may be signifi-
cantly associated with the hepatitis virus type and the initial tu-
mor diameter. Unlike the tumor diameter, the hepatitis virus type 
is a host factor, which suggests that the HCC growth rate may 
vary depending on the individual patient. In our study population, 
HCC grew faster in patients infected with HBV than in those in-
fected with HCV. Although one previous study reported a shorter 
mean TVDT among HBsAg-positive patients (48 days for HBsAg-
positive vs. 140 days for HBsAg-negative),14 other studies did not 
find a significant relationship between HCC growth rate and the 
presence of HBsAg.15,17,21 Each of the previous studies had rela-
tively small numbers of patients overall and even smaller numbers 
in each subgroup (HBsAg positive and HBsAg negative). The re-
sulting lack of statistical power in each study may have led to an 
increased probability of type II errors. In addition, most of the 
previous studies grouped patients with HCV infection and pa-
tients with no hepatitis virus infection together as “HBsAg-nega-
tive patients” and therefore could have not evaluated a potential 
difference in HCC growth rate between patients infected with 
HBV and those infected with HCV. Our results suggest that their 
estimates of HCC growth rates in patients with HCV infection may 
have been higher if the previous studies grouped the patients 
with HCV infection separately from those with no hepatitis virus 
infection. 
It is reported that the etiology of HCC affects the characteristics 
of HCC.25,26 Different HCC gene expression profiles are associated 
with different chronic liver disease etiologies,27-29 which may lead 
to different tumor behaviors in patients infected with HBV and 
HCV. Furthermore, the morphologic and molecular characteristics 
of chronic viral liver disease vary significantly based on the virus 
type, and the resulting differences in the underlying liver paren-
chyma may impact on HCC growth through the interactions be-
tween cancer cells and the surrounding parenchyma.30,31 Although 
our finding revealed that HBV-associated HCC may grow faster 
than HCV-associated HCC, the underlying mechanism for this dis-
parity remains uncertain. To our knowledge, no direct comparison 
was made between HBV- and HCV-transformed cells, regarding 
cell growth rate in vitro.31 It is of interest to define the molecular 
mechanism underlying the faster growth of HBV-associated HCC, 
but this is beyond the scope of this study.
In our study population, the TVDT of HCC increased with in-
creasing tumor size, which is consistent with the results of previous 
studies.15,21 These results suggest that HCCs do not grow exponen-
tially. Malignant tumors frequently undergo non-exponential 
growth, as the tumor growth pattern varies depending on the tu-
mor characteristics and the environment.32 A sigmoidal growth 
model could explain an inverse relationship between the tumor 
growth rate and the tumor size, and several types of human can-
cer are reported to show such a growth pattern.33-35 One possible 
explanation for tumors following a sigmoidal growth pattern is 
that only the tumor cells near the tumor boundary have access to 
Figure 2. Scatter plot and linear regression line for the relationship be-
tween the initial tumor diameter and the TVDT of HCC. TVDT, tumor 
volume doubling time; HCC, hepatocellular carcinoma.
Table 3. Estimated time needed for a 1-cm increase in tumor diameter based on the initial tumor diameter and virus type
Diameter change
Estimated time (days)
HBV NBNC HCV Overall
1 cm → 2 cm 212 296.9 328.4 240.5
2 cm → 3 cm 144.2 198 239.7 167.2
3 cm → 4 cm 115.8 192.7 212.5 141.1
4 cm → 5 cm 101.7 203 205.2 130.1
HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, Non-B Non-C.
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enough nutrients for growth.32 
The growth rate of HCC could be intimately intertwined with 
the recall strategy for non-invasive HCC diagnosis. The AASLD 
and EASL guidelines both state that any new nodule less than 1 
cm in diameter cannot be diagnosed as HCC and should be fol-
lowed up until the nodule grows to the point at which it can be 
diagnosed by imaging criteria. They recommend follow-up every 4 
months for the first year and every 6 months thereafter.9 In our 
study, the average time required for an HCC to grow from 1 cm to 
2 cm in diameter was 212 days for patients with HBV infection 
and 328.4 days for patients with HCV infection. We suggest dif-
ferent follow-up intervals for indeterminate small (<1 cm) nodules 
detected on surveillance tests in patients infected with HBV or 
HCV.
Our study has a few shortcomings. First, our study population is 
biased because we only included patients for whom TVDT was 
obtainable. Second, most of the HCCs included in the study were 
diagnosed radiologically without biopsy. We strictly followed the 
AASLD Practice Guidelines for radiologic diagnosis, which have 
been prospectively validated by a study that reported high posi-
tive predictive values for such diagnoses (MRI alone, 97.4%; com-
bined MRI and contrast-enhanced ultrasonography, 100%).2,36 
Furthermore, we believe that a radiologic diagnosis better reflects 
real clinical situations, where treatment decisions for high-risk pa-
tients are made when HCC is suspected based on imaging stud-
ies. Third, TVDT was calculated on the assumption that a tumor is 
spherical in shape, although a tumor can have a variety of shapes. 
In conclusion, we found that untreated early-stage HCC grew 
faster in patients infected with HBV than in those infected with 
HCV. This viral factor may be used as a reference when determin-
ing surveillance or recall policy for HCC. 
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